Sarah Fryer is a Director on the Board of the ICR, a membership-led, not for profit, independent association for clinical research professionals, in commercial and non-commercial environments.
The ICR has three guiding principles: Developing Professionals; Sharing Knowledge; and Raising Standards. It promotes good relations with other healthcare related groups, including the BIA, and provides:
Sarah has worked in clinical development for more than 30 years, with the last 20 years focusing on clinical QA. The majority of her career has been spent working in contract research and consultancy roles, supporting early phase biopharma companies as they move from research into clinical development. She was co-founder of Gregory Fryer Associates and founder of QRC Consultants and is now working as an independent GCP QA consultant as Director of Green End Barns Consulting Ltd.
She has been a long term member of the ICR and is also a Fellow of the Research Quality Assurance and a member of the Royal Society of Biology.
Her particular interest is the importance of quality and regulatory compliance in clinical research and brings this interest with enthusiasm to her role on the Board of the ICR.
Dr Rebecca Godfrey is the COO at ExpressionEdits, a Cambridge-based biotechnology company optimizing protein expression using AI and proprietary intronization technology. At ExpressionEdits Rebecca provides leadership and strategic direction to all business, financial and operational aspects of the organisation, leading on all commercial partnership activities.
Rebecca’s extensive track record of building highly successful organizations, teams, and systems, covers all stages of the product lifecycle, across a wide variety of therapeutic modalities and in all regions worldwide, including emerging markets. Rebecca has held Director level roles at Eisai and AbbVie and the role of Global Head Regional PV Excellence at Roche. Rebecca’s most recent roles include COO at healthtech start-up, OKKO Health, and Research Chief of Staff for the clinical-stage gene therapy biotech, Freeline Therapeutics (now Spur Therapeutics).
Rebecca also serves as Chair of the Board of Teens Unite fighting cancer and is author of the best-selling book ‘The Leadership Vaccine: Drive innovation, increase efficiency and build resilience in highly regulated industries’.
Roland has served as Chief Executive of Cambridge University Hospitals NHS Foundation Trust (CUH) since 2015.
The trust is a high performing centre for clinical care and patient experience, running the UK's most digitally developed hospitals and making award-winning use of digital systems to improve patient care. From 2018 to 2021, he was the accountable officer for the integrated care system in Cambridgeshire and Peterborough. The integrated care system and the hospital trust are focused on innovation and improvement, working alongside universities and industry to deliver this.
Aligned with these roles, Roland chaired the Shelford Group of ten teaching hospitals from 2020–2023; and in March 2023 was appointed as the NHS England National Director for Life Sciences. This position works alongside the Innovation, Research and Life Sciences (IRLS) team in NHSE to engage national innovation partners, local systems, industry, and research charities to develop a clear blueprint for how the NHS can best support, and benefit from, a strong life sciences ecosystem. During March 2023 Roland became a Governor of The Health Foundation, focussed on innovation and life sciences.
Before joining CUH, Roland was Chief Executive, Chief Operating Officer and Strategy Director at King’s College Hospital NHS Foundation Trust. He began his career in the field of corporate law at Linklaters, based in London and Hong Kong, and later moved to McKinsey to work in strategy consultancy.
